KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Total Liabilities (2016 - 2025)

Thermo Fisher Scientific's Total Liabilities history spans 17 years, with the latest figure at $56.9 billion for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 19.27% year-over-year to $56.9 billion, compared with a TTM value of $56.9 billion through Dec 2025, up 19.27%, and an annual FY2025 reading of $56.9 billion, up 19.27% over the prior year.
  • Total Liabilities for Q4 2025 was $56.9 billion at Thermo Fisher Scientific, up from $52.0 billion in the prior quarter.
  • The five-year high for Total Liabilities was $56.9 billion in Q4 2025, with the low at $30.8 billion in Q3 2021.
  • Average Total Liabilities over 5 years is $48.4 billion, with a median of $51.2 billion recorded in 2024.
  • Year-over-year, Total Liabilities soared 67.61% in 2022 and then decreased 8.2% in 2024.
  • Tracing TMO's Total Liabilities over 5 years: stood at $54.3 billion in 2021, then decreased by 2.11% to $53.1 billion in 2022, then fell by 2.11% to $52.0 billion in 2023, then decreased by 8.2% to $47.7 billion in 2024, then rose by 19.27% to $56.9 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Total Liabilities are $56.9 billion (Q4 2025), $52.0 billion (Q3 2025), and $50.8 billion (Q2 2025).